GB virus C as a potential vaccine against human immunodeficiency virus: A review

Abstract

Human immunodeficiency virus (HIV) is a pathogenic virus capable of entering the human body and replicating within T cells, ultimately leading to acquired immunodeficiency syndrome. In contrast, GB-virus C (GBV-C), a member of the Flaviviridae family, also infects humans but, according to current studies, is not associated with any known pathogenic effects. Unlike most RNA viruses, GBV-C encodes a single polyprotein. It is primarily transmitted through blood and sexual contact. GBV-C comprises three strains: GBV-C, hepatitis G virus (HGV), and other less-studied strains. The HGV strain has been detected in patients with liver cirrhosis; however, there is no evidence that it causes liver disease. Notably, GBV-C reduces immune activation in HIV-infected patients. It has been shown to have a significant effect on the target cell receptors for HIV, indicating its potential as a model for vaccine development against HIV. However, there is a lack of information and studies concerning this virus. GBV-C-based vaccine development faces many challenges, such as concerns about safety and efficacy, limited understanding of its mechanisms of action and immunogenicity, HIV strain variability, ethical and regulatory considerations, production and delivery logistics, long-term outcomes, and public perception and acceptance. Nevertheless, bioinformatic techniques can play a crucial role in overcoming these challenges through approaches such as comparative genomics, epitope mapping, structural bioinformatics, and vaccine design and optimization.

Keywords

GB virus-C / Hepatitis G virus / Human immunodeficiency virus / Acquired immunodeficiency syndrome / Bioinformatics

References

[1] U.S. Department of Health and Human Services. The HIV Life Cycle . National Institutes of Health; 2021. Available from: https://hivinfo.nih.gov/understanding/hiv/fact/sheets/hiv-life-cycle [Last accessed on 2025 Jan 20].

[2] Rogovski P, Cadamuro RD, Da Silva R, et al. Uses of bacteriophages as bacterial control tools and environmental safety indicators. Front Microbiol. 2021; 12:793135. doi: 10.3389/fmicb.2021.793135

[3] Stark LA. Beneficial microorganisms: Countering microbephobia. CBE Life Sci Educ. 2010; 9(4):387-389. doi: 10.1187/cbe.10-09-0119

[4] George SL, Varmaz D. What you need to know about GB virus C. Curr Gastroenterol Rep. 2005; 7(1):54-62. doi: 10.1007/s11894-005-0067-0

[5] Bhattarai N, Stapleton JT. GB virus C: The good boy virus? Trends Microbiol . 2012; 20(3):124-130. doi: 10.1016/j.tim.2012.01.004

[6] Zhang W, Chaloner K, Tillmann H, Williams C, Stapleton J. Effect of early and late GB virus C viraemia on survival of HIV-infected individuals: A meta-analysis. HIV Med. 2006; 7(3):173-180. doi: 10.1111/j.1468-1293.2006.00366.x

[7] Mulrooney-Cousins PM, Michalak TI. Molecular testing in hepatitis virus related disease. In: Diagnostic Molecular Pathology . Netherlands: Elsevier; 2017. p. 63-73. doi: 10.1016/B978-0-12-800886-7.00006-6

[8] Christensen PB, Fisker N, Mygind LH, et al. GB virus C epidemiology in Denmark: Different routes of transmission in children and low- and high-risk adults. J Med Virol. 2003; 70(1):156-162. doi: 10.1002/jmv.10359

[9] Pavesi A. Origin and evolution of GBV-C/Hepatitis G virus and relationships with ancient human migrations. J Mol Evol. 2001; 53(2):104-113. doi: 10.1007/s002390010198

[10] Mukaide M, Mizokami M, Orito E, et al. Three different GB virus C/hepatitis G virus genotypes. Phylogenetic analysis and a genotyping assay based on restriction fragment length polymorphism. FEBS Lett. 1997; 407(1):51-58. doi: 10.1016/s0014-5793(97)00136-1

[11] Jain A, Kar P, Gopalkrishna V, Gangwal P, Katiyar S, Das BC. Hepatitis G virus (HGV) infection & its pathogenic significance in patients of cirrhosis. Indian J Med Res. 1999; 110:37-42.

[12] Ramia S, Al Faleh FZ. Hepatitis G virus (HGV) and liver diseases. Saudi J Gastroenterol. 1999; 5(2):50-55.

[13] Maidana-Giret MT, Silva TM, Sauer MM, et al. GB virus type C infection modulates T-cell activation independently of HIV-1 viral load. AIDS. 2009; 23(17):2277-2285. doi: 10.1097/QAD.0b013e32832d7a11

[14] Stapleton JT, Foung S, Muerhoff AS, Bukh J, Simmonds P. The GB viruses: A review and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus. J Gen Virol. 2011; 92(Pt 2):233-246. doi: 10.1099/vir.0.026989-0

[15] Bhattarai N, McLinden JH, Xiang J, Kaufman TM, Stapleton JT. GB virus C envelope protein E2 inhibits TCR-induced IL-2 production and alters IL-2-signaling pathways. J Immunol. 2012; 189(5):2211-2216. doi: 10.4049/jimmunol.1201324

[16] Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation, and HIV disease. Trends Microbiol. 2013; 21(1):6-13. doi: 10.1016/j.tim.2012.09.001

[17] Stapleton JT, Martinson JA, Klinzman D, Xiang J, Desai SN, Landay A. GB virus C infection and B-cell, natural killer cell, and monocyte activation markers in HIV-infected individuals. AIDS. 2013; 27(11):1829-1832. doi: 10.1097/QAD.0b013e328363089f

[18] George SL, Varmaz D, Stapleton JT. GB virus C replicates in primary T and B lymphocytes. J Infect Dis. 2006; 193(3):451-454. doi: 10.1086/499435

[19] Verma A, Singh U, Mallick P, Dwivedi P, Singh A. NeuroAIDS and omics of HIVvpr. J Med Microbiol Immunol Res . 2012; 1:477-512.

[20] Mount DW. Bioinformatics: Sequence and Genome Analysis . United States: Cold Spring Harbor Laboratory Press; 2006.

[21] Setubal JC, Stadler PF, Stoye J. Comparative Genomics: Methods and Protocols . Totowa: Humana Press; 2024.

[22] Martini S, Nielsen M, Peters B, Sette A. The immune epitope database and analysis resource program 2003-2018: Reflections and outlook. Immunogenetics . 2019; 72(1-2):57-76. doi: 10.1007/s00251-019-01137-6

[23] Mohan CG. Structural Bioinformatics: Applications in Preclinical Drug Discovery Process . Berlin: Springer; 2019.

[24] Thomas S. Vaccine design. In: Vaccines for Human Diseases: Methods and Protocols . Vol. 1. Totowa: Humana Press; 2022.